NCT03844386View on ClinicalTrials.gov

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

November 11, 2021

Study Completion Date

April 4, 2022

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

MVA.tHIVconsv3

viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1

BIOLOGICAL

MVA.tHIVconsv4

viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1

OTHER

Placebo

The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.

Trial Locations (1)

27514

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03844386 - Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults | Biotech Hunter | Biotech Hunter